Cagrilintide Explained: The Amylin Analog Behind CagriSema

Cagrilintide is not a GLP-1 drug. It is a long-acting copy of amylin, a hormone that signals fullness, and it works through its own pathway. That difference is exactly why researchers pair it with semaglutide instead of using it to replace one. Paired as CagriSema, the two cut body weight by 20.4% in a large Phase 3 trial, and Novo Nordisk filed it with the FDA in December 2025.

This guide covers what cagrilintide is, what the trials found, how it compares with tirzepatide and retatrutide, and what to check when you buy it for lab work.

Key Takeaways

• Cagrilintide is a long-acting amylin analog with a fatty acid attached. It switches on the amylin receptors (AMY1R, AMY2R and AMY3R) and the calcitonin receptor, and works on fullness and stomach emptying instead of the GLP-1 system.
• Its half-life is about 159 to 195 hours, roughly a week, so studies give it once a week. CAS number 1415456-99-3, molecular weight about 4409 Da.
• In the Phase 3 REDEFINE 1 trial, cagrilintide plus semaglutide (CagriSema) cut body weight by 20.4% at 68 weeks against 3.0% on placebo, and by about 22.7% in people who stayed on treatment.
• Amylin and GLP-1 work through separate pathways that add up, which makes cagrilintide the leading partner for combination research with GLP-1, dual and triple agonists.
• Quality matters: look for third-party HPLC verification, a batch-specific COA, and purity above 99% before any reconstitution work.
• Lyze Labs supplies pharmaceutical-grade cagrilintide for research use only, with free discreet worldwide shipping and per-batch certificates of analysis.

What Cagrilintide Is and How It Works

Cagrilintide, first called AM833, is a lab-made version of human amylin. The pancreas releases amylin together with insulin after a meal. Natural amylin is unstable and lasts only minutes, which makes it useless as a long-acting research tool. Cagrilintide fixes this with a fatty acid (C20) attached to its front end through a small linker. The fatty acid makes it ride on albumin in the blood, so it lasts about a week (Enebo, 2021).

It switches on the whole amylin receptor family and the calcitonin receptor. In research models it acts in the brain's appetite centers (the area postrema and the hypothalamus) to signal fullness. One of its best-studied effects is slowing how fast the stomach empties, which keeps the feeling of fullness going. In 2026, cryo-EM structures showed exactly how cagrilintide binds both the AMY1 and calcitonin receptors, explaining why it switches on both (Gu, 2026).

The key point: cagrilintide works entirely outside the GLP-1 pathway. That separation is the whole reason it is combined with GLP-1 drugs.

Why Researchers Are Interested: The CagriSema Data

CagriSema, cagrilintide plus semaglutide, is what put cagrilintide on the map. The Phase 3 REDEFINE program produced the data.

REDEFINE 1 followed 3,417 adults with overweight or obesity for 68 weeks. CagriSema cut body weight by 20.4%, against 3.0% on placebo, and more than either drug alone (Garvey, 2025). Among people who stayed on treatment, the figure was about 22.7%. REDEFINE 2, in people with type 2 diabetes, also succeeded: 13.7% against 3.4% on placebo (Davies, 2025). On cagrilintide alone, the Phase 2 trial found up to 10.8% weight loss at 26 weeks (Lau, 2021).

What makes these numbers matter to researchers is that the two mechanisms added up. Together they did more than either alone.

How Cagrilintide Compares to Tirzepatide and Retatrutide

The newest weight research is defined by how compounds combine receptor targets. Cagrilintide stands apart as the only major candidate that does not touch the gut-hormone (incretin) system at all.

Tirzepatide switches on the GLP-1 and GIP receptors, and that dual action is credited with its strong results against GLP-1-only drugs. Retatrutide goes further and adds the glucagon receptor, which raises the energy the body burns. For both, see the retatrutide vs tirzepatide vs semaglutide comparison.

Cagrilintide adds the amylin pathway, a fullness signal that adds to the incretin signals instead of repeating them. That is precisely why the CagriSema combination worked: it stacked two independent appetite-regulation systems. The same logic now reaches the triple agonists. No human trial has combined cagrilintide with retatrutide, but a 2026 study in obese rats did, and the pair cut more weight than either alone and more than cagrilintide with semaglutide or tirzepatide (Petersen, 2026). See the cagrilintide vs retatrutide comparison for more.

In short, cagrilintide is not a rival to the incretin compounds. It is their research partner. Ready-made, the pairing is our cagrilintide and semaglutide blend.

What to Look For in a Quality Reference Compound

Because cagrilintide is a complex 4409 Da acylated peptide, manufacturing quality varies enormously across suppliers. Impurities, cut-short chains and a missing fatty acid can all spoil a study. Before any laboratory uses a batch, three things should be verified.

First, third-party HPLC analysis confirming purity above 99%. High-performance liquid chromatography is the standard for separating and quantifying peptide-related impurities, and a reputable supplier will have this run by an independent lab. Second, a batch-specific certificate of analysis (COA) rather than a generic marketing document. The vendor should be able to tell you which batch your order came from. Third, mass spectrometry confirming the expected weight of about 4409 Da. Our guide on how to verify research peptide purity with a COA walks through reading these documents line by line, and our piece on research peptide scam red flags covers the warning signs of low-grade material. Every batch of cagrilintide from Lyze Labs has a per-batch COA published online and is HPLC tested above 99% purity.

Reconstitution and Storage Notes (Research Framing)

Keep the freeze-dried powder cold and away from light and moisture until use. Most labs store unmixed vials frozen for long-term stability.

To mix, add bacteriostatic water gently down the side of the vial rather than straight onto the powder, then swirl; do not shake. Once mixed, keep the solution in the fridge and use it within a set window. These are general handling notes for laboratory work, not a usage protocol. For the full method, see how to reconstitute research peptides and peptide storage and stability.

Sourcing Cagrilintide for Research

Lyze Labs supplies pharmaceutical-grade cagrilintide for research and laboratory use only, manufactured to research-grade standards and verified by third-party HPLC at purity above 99%, with a certificate of analysis available for every batch. Each kit is ten vials from one batch, in 5 mg or 10 mg vials.

Researchers in 150+ countries order from us, with 10,000+ orders shipped. Orders paid before the daily batch closes are processed that day. Shipping is free and tracked, most orders arrive in 7 to 14 days, and delivery is guaranteed. You can pay by Visa, Mastercard, Amex, PayPal, Apple Pay, Google Pay, bank transfer, local wallets and bank apps in your region, or crypto (USDT, USDC, BTC).

Frequently Asked Questions

What is cagrilintide and how does it differ from GLP-1 compounds?

Cagrilintide is a long-acting amylin analog. It switches on amylin receptors and the calcitonin receptor, which affect fullness and stomach emptying in research models. Unlike semaglutide, tirzepatide or retatrutide, it does not act on GLP-1 or the other gut-hormone receptors at all. That makes it a partner to those compounds rather than a substitute.

Why is cagrilintide combined with semaglutide in CagriSema?

Because amylin and GLP-1 work through separate, non-redundant satiety pathways, combining them stacks two independent appetite-regulation mechanisms. In the Phase 3 REDEFINE 1 trial, the combination cut body weight by 20.4% at 68 weeks, more than either drug alone.

How does cagrilintide compare to retatrutide and tirzepatide?

Tirzepatide switches on GLP-1 and GIP receptors, and retatrutide adds the glucagon receptor; both work within the gut-hormone system. Cagrilintide adds a separate amylin pathway. No human trial has combined it with retatrutide, but a 2026 rat study found the pair cut more weight than either alone. See the tirzepatide kit for that compound.

What are the key specifications of cagrilintide?

Cagrilintide has CAS number 1415456-99-3 and a molecular weight of about 4409 Da. Its half-life is about 159 to 195 hours, thanks to a C20 fatty acid, so studies give it once a week. It is an investigational compound for research use only and is not approved for human use.

How should research-grade cagrilintide be verified for quality?

Look for third-party HPLC analysis confirming purity above 99%, a batch-specific certificate of analysis for the batch your order ships from, and mass-spectrometry confirmation of the expected molecular weight. Generic documents, or a vendor who cannot say which batch you received, are warning signs. Every Lyze Labs batch has a per-batch COA published online and independent HPLC verification.

Is cagrilintide approved for human use?

No. Cagrilintide is an investigational compound, and CagriSema is still awaiting an FDA decision. All material supplied by Lyze Labs is strictly for research and laboratory use only. Nothing in this guide is medical advice or a usage protocol.

Order cagrilintide from the kit page; a person confirms your order and answers questions, day or night. Every batch ships free worldwide with discreet packaging and a verified certificate of analysis.

Studies Cited

• Garvey WT, et al. (2025). Coadministered cagrilintide and semaglutide in adults with overweight or obesity. New England Journal of Medicine.
• Davies MJ, et al. (2025). Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. New England Journal of Medicine.
• Lau DCW, et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a dose-finding phase 2 trial. The Lancet.
• Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg: a phase 1b trial. The Lancet.
• Gu YM, et al. (2026). Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors. Acta Pharmacologica Sinica.
• Petersen J, et al. (2026). Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nature Metabolism.